Australian Pharmaceutical Industries Limited provided earnings guidance for the half year ending February 28, 2018 and full year 2018. For the half year, the company expected net profit after tax will be approximately $26.5 million. The half year result is therefore expected to be down approximately 9% on the prior corresponding period. The first half result was driven by the suppressed retail conditions experienced by its Priceline Pharmacy network, which persisted until late in the key Christmas trading period. For the full year 2018, the company expected net profit after tax is to be marginally above that of full year 2017. The company announced overall network sales, including dispensary, for the financial year to date were up 2% while the like-for-like front-of-store sales in its network had declined 2.4% for the period.